Dark Mode
Individualized Neoantigen Therapy Immunogenicity Data
Data Science and Analytics
Tags and Keywords
Trusted By
"No reviews yet"
Free
About
Presents an in-depth analysis of T-cell responses observed during the Phase 1 KEYNOTE-603 study following individualized neoantigen therapy (mRNA-4157, or V940). The data set is derived from patients with resected non–small cell lung cancer and cutaneous melanoma. It includes key immunological and molecular details, such as peptide sequences, HLA types, and specific T-cell response metrics, offering a crucial resource for analysing the immunogenicity of this personalized cancer treatment.
Columns
- SUBJID: A unique identifier assigned to each individual patient included in the study.
- Gene: Identifies the specific Human Leukocyte Antigen (HLA) gene associated with the alleles recorded.
- Allele1: Provides the sequence information for the first allele corresponding to the specified HLA gene.
- Allele2: Provides the sequence information for the second allele corresponding to the specified HLA gene.
Distribution
The dataset is primarily available in a tabular format, typically CSV. The HLA typing data file,
hla_types.csv, contains 176 valid records across 4 columns, including patient identification and HLA gene information. The data focuses on patient-specific metrics, peptide sequences, and pool assignment metrics.Usage
Ideal for Immunogenicity Analysis to determine the ability of mRNA-4157 to induce specific T-cell responses. Supports Therapeutic Development by providing molecular insights essential for advancing individualized neoantigen therapies. Valuable for Clinical Research focused on patient outcomes and T-cell kinetics. Can also assist in Biomarker Discovery efforts aimed at predicting patient response to V940 therapy.
Coverage
The data relates to subjects enrolled in the Phase 1 KEYNOTE-603 clinical trial. The patient population consists of individuals with resected non–small cell lung cancer and cutaneous melanoma. The set includes data representing 16 unique patient IDs, focusing specifically on their neoantigen sequences, HLA types, and T-cell responses.
License
Attribution 4.0 International (CC BY 4.0)
Who Can Use It
Immunologists studying neoantigen presentation and T-cell activation mechanisms. Oncology Researchers assessing personalized vaccine efficacy and molecular predictors of clinical response. Drug Developers focused on designing and testing next-generation individualized cancer therapies.
Dataset Name Suggestions
- mRNA-4157 T-Cell Response Analysis
- Individualized Neoantigen Therapy Immunogenicity Data
- KEYNOTE-603 HLA and Peptide Sequences
Attributes
Original Data Source: Individualized Neoantigen Therapy Immunogenicity Data
QUALITYLoading...